The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Interim [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
Abstract
Purpose: The prognostic value of [ 18 F]fluorodeoxyglucose–positron emission tomography (PET), interpreted according to visual criteria, is a matter of debate for diffuse large B-cell lymphoma (DLBCL). Moreover, most published studies do not differentiate between patients treated with or without rituximab. We retrospectively investigated the prognostic value of PET performed in patients with DLBCL receiving chemotherapy plus rituximab. Images were interpreted both visually and by computing maximum standardized uptake value (SUV max ) between PET performed at baseline and after two cycles of chemotherapy. Patients and Methods: One hundred twelve patients newly diagnosed with DLBCL were treated with an anthracycline-based regimen plus rituximab. A PET was performed after two cycles of treatment. PET positivity or negativity was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier analysis. Results: Visual analysis showed that 70 patients (62.5%) presented with a negative PET scan after two cycles of treatment. The 3-year PFS and OS rates were 84% and 88%, respectively, in patients with PET-negative results versus 47% and 62%, respectively, in patients with PET-positive results (P < .0001 and P < .003, respectively). A second analysis was performed on 85 patients by using interim PET in a quantitative approach on the basis of a ΔSUV max evaluation of more than 66%. The 3-year PFS was 77% for patients with PET-negative results and 37.5% for patients with PET-positive results (P = .002). Conclusion: An early PET scan after two cycles of treatment can effectively predict the outcome in patients with DLBCL treated with rituximab and anthracycline-based chemotherapy by using either a visual or quantitative approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Cited by
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5246 · Cited by 497
Self-citationMikhaeel, N. G., Smith, D., Dunn, J. T., Phillips, M., Møller, H., Fields, P. A., Wrench, D., & Barrington, S. F. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3315-7 · Cited by 295
Itti, E., Meignan, M., Berriolo-Riedinger, A., Biggi, A., Cashen, A. F., Véra, P., Tilly, H., Siegel, B. A., Gallamini, A., Casasnovas, R.-O., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2435-6 · Cited by 255
Self-citation
Metadata
- Authors
- Safar, V., Dupuis, J., Itti, E., Jardin, F., Fruchart, C., Bardet, S., Véra, P., Copie-Bergman, C., Rahmouni, A., Tilly, H., Meignan, M., & Haioun, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-01-10
- Volume
- 30
- Issue
- 2
- Pages
- 184-190
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102472975
- Cited by
- 162
- References
- 1
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interim [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab. https://app.cochat.ai/papers/10.1200/jco.2011.38.2648
- The paper
- Safar, V., Dupuis, J., Itti, E., Jardin, F., Fruchart, C., Bardet, S., Véra, P., Copie-Bergman, C., Rahmouni, A., Tilly, H., Meignan, M., & Haioun, C. (2012). Interim [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.38.2648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.